[ACN Newswire] – By Ivan DeryuginThe biotechnology sector is one where growth is, for the most part, fueled by a single factor: new drugs. Companies that develop the next generation of drugs for a market stand to gain … moreView todays social media effects on ABTView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Abbott Park, Illinois (NYSE: ABT) – Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented … moreView todays social media effects on ABTView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingWith Gilead’s (NASDAQ:GILD) reported 100% Hepatitis C virologic response rate over the weekend, rivals Achillion (NASDAQ:ACHN) and Vertex (NASDAQ:VRTX) traded down 15% and 5% respectively at … moreView todays social media effects on ABTView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Abbott Park, Illinois P(NYSE: ABT) – Abbott today announced the first long-term patient-reported health outcomes data from an open-label analysis of the ongoing, Phase 3 ABILITY-1 trial of HUMIRA® (adalimumab). … moreView todays social media effects on ABTView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Abbott Park, Illinois (NYSE: ABT) – Results from Abbott’s phase 2b clinical trial, Aviator, demonstrated high sustained viral response rates at 12 weeks post-treatment (SVR12) in all 8- and … moreView todays social media effects on ABTView the latest stocks trending across Twitter. Click to view dashboard […]
